FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib

BACKGROUND: Sorafenib, a multi-kinase inhibitor, is used as a standard therapy for advanced hepatocellular carcinoma (HCC). However, complete remission has not been achieved and the molecular basis of HCC resistance to sorafenib remains largely unknown. Previous studies have shown that fibroblast gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Lixia, Wang, Xuli, Tang, Yaoliang, Huang, Shuang, Hu, Chien-An Andy, Teng, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223586/
https://www.ncbi.nlm.nih.gov/pubmed/28069043
http://dx.doi.org/10.1186/s13046-016-0478-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223586/
https://www.ncbi.nlm.nih.gov/pubmed/28069043
http://dx.doi.org/10.1186/s13046-016-0478-9

Ejemplares similares